PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)
A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response
Sponsor: Incheon St.Mary's Hospital
A PHASE4 clinical study on Chronic Hepatitis C, this trial is ongoing. The trial is conducted by Incheon St.Mary's Hospital and has accumulated 8 data snapshots since 2010. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Feb 2024 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Sep 2022 — Feb 2024 [monthly]
Unknown Status PHASE4
▶ Show 3 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Incheon St.Mary's Hospital
- Inje University
- Inje University Haeundae Paik Hospital
- Inje University Ilsan Paik Hospital
- Pusan National University Hospital
- Pusan National University Yangsan Hospital
- Severance Hospital
- Soon Chun Hyang University
For direct contact, visit the study record on ClinicalTrials.gov .